home / stock / xrtxf / xrtxf news

XRTXF News and Press, XORTX Therapeutics Inc From 08/19/20

Stock Information
Company Name: XORTX Therapeutics Inc
Stock Symbol: XRTXF
Market: OTC
Website: xortx.com
Menu
XRTXF XRTXF Quote XRTXF Short XRTXF News XRTXF Articles XRTXF Message Board
Get XRTXF Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTXF - XORTX Therapeutics Moves Toward Phase 3 Trials to Help with an "Orphan" Kidney Disease and COVID-19 Kidney Injuries

e Research Corp. ( www.eresearch.com ) published a 33-page initiation equity Research Report on XORTX Therapeutics Inc. (CSE:XRX ; OTC:XRTXF). e Research initiated coverage with a "Speculative Buy" rating and one-year price target of $2.30. XORTX is focused on kidney diseases with the ...
XRTXF - XORTX Partners with Mount Sinai's Icahn School of Medicine on US-based Clinical Trial in COVID-19

CALGARY, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a partnership wi...

XRTXF - XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs

CALGARY, Alberta, May 19, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX) (OTCQB: XRTXF) (FRANKFURT: ANU1), a biopharmaceutical company focused on developing innovative therapies to treat kidney disease, is pleased to provide the foll...

XRTXF - XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials

CALGARY, Alberta, April 30, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX) (OTCQB: XRTXF) (FRANKFURT: ANU1), a biopharmaceutical company focused on developing innovative therapies to treat kidney disease announces that it has granted...
XRTXF - XORTX Provides Overview and Update of Key Activities

CALGARY, Alberta, April 30, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed...

XRTXF - XORTX Announces New Clinical Advisory Board Member

CALGARY, Alberta, March 26, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat polycystic kidney disease (PKD), is pleased to announce that D...

XRTXF - XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury Due to Coronavirus Infection

CALGARY, Alberta, March 16, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late stage clinical programs, ...
XRTXF - XORTX Launches XRx-101, A New Program to Treat Coronavirus COVID-19 Infection

• XRx-101 – a triple action approach to suppressing COVID-19 Injury • CALGARY, Alberta, March 16, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on develop...

XRTXF - XORTX Announces Re-Pricing of Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Jan. 31, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on dev...

XRTXF - XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)

● TMX-049 Results Show Beneficial Decrease of Urinary Albumin in T2DN ● CALGARY, Alberta, Sept. 19, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing inn...
Previous 10 Next 10